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Multivariable Regression Analysis for OS and NRS† Post-
transplant variables at day 90 (±7) post-allo HCT §
OS NRS
Hospital stay (#5 vs. .5 days)* NS NS
Days of TPN (.0 vs. 0)* NS NS
PRBC transfusion (.0 vs. 0)* NS NS
Platelets transfusion (.0 vs. 0)* NS NS
Pneumonia episodes (.0 vs. 0)*,U NS p50.0008; 2.8
(1.5, 5.1)
Episodes of CMV reactivation
(.0 vs. 0)*
NS NS
Cumulative dose of steroids
(\2,650mg vs. $ 2,650mg)*
NS p50.001; 0.4
(0.2, 0.7)
Total days of steroids (\60 vs. $60)* NS NS
Dose of steroid at day 90 (67)
(\20 vs. $20mg/day)
NS NS
% weight loss (#10% vs. .10%)** NS NS
Acute GVHD (max grade) 0-I vs.
II vs. III-IV
NS NS
KPS at day 90 (67) (\80 vs. $80) p\0.0001; 4.7
(3.0, 7.4)
p\0.0001; 3.9
(2.0, 7.5)
Total bilirubin at day 90 (67)
(\1.1 vs. $1.1mg/dl)
NS NS
% Creatinine change ($30
vs.\30)*
p50.0002; 2.2
(1.5, 3.3)
NS
Albumin at day 90 (67)
\ 3.0 g/dl
vs. . 3.5 g/dl; 3.0-3.5 g/dl vs.
. 3.5 g/dl
p50.006; 2.5
(1.4, 4.5);
1.5 (0.9, 2.3)
p50.01; 3.2
(1.4, 7.1); 1.2
(0.6, 2.3)
Additional immunosuppressive
therapy (ies) (.0 vs. 0)^
NS NS
Additional anti-microbial(s)
(.0 vs. 0)^^
p50.002; 2.8
(1.5, 5.3)
NS
†Table entry: p-value (p) for the covariate effect;Hazard ratio (HR) (95%
CI).
§The effects of post-transplant variables were adjusted for baseline vari-
ables such as age, KPS and patient/donor CMV statuses in this regres-
sion, whenever appropriate/necessary. Statistical significance defined
as\0.05; NS: not significant (p$0.05). TPN: total parenteral nutrition.
*from hematopoietic engraftment until day 90 (67).
**from initiation of conditioning chemotherapy (baseline) until day 90
(67).
^additional anti-GVHD therapy(ies) apart from standard GVHD prophy-
laxis and glucocorticoids until day 90 (67).
^^additional antimicrobials apart from acyclovir, fluconazole or vorico-
nazole (whenever used for primary prohylaxis) and trimethoprin-
sulfamethoxazole (or equivalents).
Udevelopment of infiltrates requiring additional/alternative antimicro-
bials.
6 Oral Presentationscarcinoma infrequent after allo-HCT, we hypothesized that GI
could be observed in oral mucosal cells but not in nasal mucosal cells
of long-term HCT survivors.
Methods:We examined epithelial cells from buccal and nasal mu-
cosa of 71 subjects for GI at 15 microsatellite loci spanning 14 human
autosomes. The study population included long-term (4–22 yrs, n5
21) and short-term (2–3 months, n 5 15) survivors of myeloablative
allo-HCT, using GVHD prophylaxis with methotrexate (day 1, 3, 6
and 11) and cyclosporine (for 3–6 months). Controls included long-
term (4–12 yrs, n5 14) and short-term (2–3 months, n5 3) survivors
of myeloablative auto-HCT, 8 patients treated with intensive che-
motherapy without HCT and 5 healthy volunteers. DNA extracted
from peripheral blood leukocytes and cells of nasal and buccal mu-
cosa was PCR amplified for a panel of 15 microsatellite markers
(ABI-Identifiler). Fragment size analysis was done to identify novel
allele peaks (one that was absent in donor and recipient blood
pre-transplant but present in recipient mucosa post-transplant)
indicative of microsatellite instability (MSI).
Results: MSI was detected in 61% long-term allo-HCT survivors
in buccal mucosa, and in 5% long-term allo-HCT survivors in nasal
mucosa (p\0.001, Fisher exact test). MSI was detected in 12% short-
term allo-HCT survivors in buccal mucosa, and in 0% short-term
allo-HCT survivors in nasal mucosa (p 5 0.48). There was no asso-
ciation between MSI and history of clinical oral GVHD. None of the
auto-HCT survivors, patients treated with chemotherapy without
HCT or healthy volunteers showed MSI in buccal or nasal mucosal
cells. No MSI was observed in blood leukocytes of any of the above
patients or controls.
Conclusion: GI in long-term allo-HCT suvivors occurs fre-
quently in oral mucosal cells but rarely in nasal mucosal cells. As
GI was not observed in the oral mucosa of auto-HCT recipients
who received similar transplant conditioning, it cannot be due to cy-
totoxic therapy, but it should be due to a factor unique to allo-HCT,
ie, immunosuppressive drugs given for GVHD prophylaxis or graft vs
host oral mucosa reaction (even if clinically silent). The graft-vs-host
oral mucosa reaction may be more likely, as the GI was frequently
observed late posttransplant (after discontinuation of prophylactic
immunossupressive drugs) and rarely early posttransplant.
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Acute GVHD (aGVHD) as a predictor of post allo-HCT survival
generally relies on criteria with significant inter-observer variability.
We study the impact of clinical, laboratory and pharmacologic pa-
rameters, during the immediate post-transplant phase [from hemato-
logic engraftment till day 90 (67)] on NRS and OS. In this analysis,
326 consecutive pts underwent allo-HCT between 09/2000 until 03/
2007; 26 pts who died within 90 days from the date of cell infusion and
3 syngeneic allo-HCT recipients were excluded from analysis. A total
of 297 (M/F 5 170/127) patients, median age 46 (range: 17–69) yrs
received an allo-HCT [MRD 5 154 (52%), MUD 5 109 (37%),
MMRD 5 3 (1%), MMUD 5 31 (10%)] using PBSC 5 261 (88%)
or BM 5 36 (12%) following myeloablative 5 99 (33%), RIC 5
174 (59%), or NMT5 24 (8%) for various hematologic malignancies
stratified by CIBMTR risk [low5 87 (30%); int5 85 (29%); high5
125 (42%)] usingvarious GVHD prophylaxis regimens [MTX-based5
244 (82%); MMF-based 5 53 (18%)]. Pre-transplant variables [sig-
nificant (p\0.05) or not-significant (NS) (p$0.05) in multivariable
Cox proportional hazards regression analysis] included: age ($55
vs.\ 55 yrs) [OS: p 5 0.035, HR 5 1.6 (95% CI: 1.0–2.4); NRS:
p 5 0.03, HR 5 2.0 (95% CI: 1.1–3.6)], donor-gender [OS: NS;
NRS: NS], cell source (BM vs. PB) [OS: NS; NRS: NS], baseline
KPS (#80 vs. .80) [OS: NS; NRS: NS], CIBMTR risk (low vs.
int. vs. high) [OS: NS; NRS: NS], regimen (myeloablative vs. RIC/
NMT) [OS: NS; NRS: NS], donor/recipient matching-status
(MRD, MUD, mismatched (ref)) [OS: p 5 0.03, MRD vs. ref:HR 5 2.7 (95% CI: 1.2–6.1), MUD vs. ref: HR 5 2.7 (95% CI:
1.2- 6.1); NRS: NS], CD341 dose (\ 3  106/kg, 3–7.9  106/kg,
$8 106/kg) [OS: NS; NRS: NS], GVHD prophylaxis (MTX-based
vs. MMF-based) [OS: NS; NRS: NS], recipient/donor CMV status
[OS: NS; NRS: NS]. Multivariable regression analysis of post-trans-
plant variables at day 90 show that a KPS\80 and hypoalbuminemia
\3.0 g/dl are independent predictors of worse NRS and OS. A wors-
ening serum creatinine ($30%) and additional antimicrobials apart
from standard prophylaxis are independent predictors of worse OS;
whereas pneumonia (.0 episode by day 90) and cumulative dose of
prednisone exceeding 2,650 mg are independent predictors of worse
NRS. A KPS \80 and hypoalbuminemia (\3.0 g/dl), at day 90,
important predictors of survival that should be considered when
prognosticating outcome after allo-HCT.12
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